for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Rigel Pharmaceuticals, Inc.

RIGL.OQ

Latest Trade

2.51USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.24

 - 

5.24

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.51
Open
--
Volume
--
3M AVG Volume
163.45
Today's High
--
Today's Low
--
52 Week High
5.24
52 Week Low
1.24
Shares Out (MIL)
168.93
Market Cap (MIL)
429.08
Forward P/E
-9.56
Dividend (Yield %)
--

Next Event

Rigel Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Rigel Pharmaceuticals - May Offer & Sell Shares Of Common Stock Having Offering Price Of Upto $65 Million From Time To Time Through Jefferies

Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, And Overviews Covid-19 Program

Rigel Announces Investigator-Sponsored Trial Of Fostamatinib In Patients With Covid-19 Pneumonia

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses on signaling pathways that are critical to disease mechanisms. The Company’s product include TAVALISSE is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase I study for its interleukin receptor associated kinase (IRAK) program. In addition, it has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.

Industry

Biotechnology & Drugs

Contact Info

1180 Veterans Blvd

SOUTH SAN FRANCISCO, CA

94080-1985

United States

+1.650.6241100

https://www.rigel.com/

Executive Leadership

Raul R. Rodriguez

President, Chief Executive Officer, Director

Dean L. Schorno

Chief Financial Officer, Executive Vice President

Dolly A. Vance

Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary

Wolfgang Dummer

Executive Vice President and Chief Medical Officer

Esteban Masuda

Senior Vice President - Research

Key Stats

1.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.1K

2020(E)

0.1K
EPS (USD)

2017

-0.620

2018

-0.440

2019

-0.400

2020(E)

-0.229
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.97
Price To Book (MRQ)
6.79
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
31.35
LT Debt To Equity (MRQ)
31.35
Return on Investment (TTM)
-21.66
Return on Equity (TTM)
-17.01

Latest News

Latest News

BRIEF-Rigel Announces Availability Of Tavlesse® In Europe

* RIGEL ANNOUNCES AVAILABILITY OF TAVLESSE® (FOSTAMATINIB DISODIUM HEXAHYDRATE) IN EUROPE

BRIEF-Rigel Reports First Quarter 2020 Financial Results

* RIGEL REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Rigel Reports Q4 Loss Per Share $0.10

* RIGEL REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Rigel Pharmaceuticals Q1 Loss Per Share $0.17

* RIGEL ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

BRIEF-Rigel Pharmaceuticals Says Expects To Report About $94.3 Mln Cash, Cash Equivalents, Short-Term Investments As Of March 31, 2018

* RIGEL PHARMACEUTICALS SAYS EXPECTS TO REPORT IT HAD ABOUT $94.3 MILLION CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AS OF MARCH 31, 2018 - SEC FILING Source text: (https://bit.ly/2Jedbsn) Further company coverage:

BRIEF-Rigel Announces Pricing Of Public Offering Of Common Stock

* PUBLIC OFFERING OF 16,000,000 SHARES OF ITS COMMON STOCK, OFFERED AT A PRICE OF $3.90 PER SHARE TO PUBLIC Source text for Eikon: Further company coverage:

BRIEF-Rigel Intends To Offer & Sell Up To 15 Mln Shares Of Its Stock In Underwritten Public Offering

* RIGEL PHARMACEUTICALS INC - INTENDS TO OFFER & SELL UP TO 15 MILLION SHARES OF ITS STOCK IN AN UNDERWRITTEN PUBLIC OFFERING

BRIEF-Rigel Pharmaceuticals NDA For Tavalisse Approved By FDA

* RIGEL PHARMACEUTICALS NDA FOR TAVALISSE APPROVED BY FDA Source text: (http://bit.ly/2HGn96a) Further company coverage:

FDA approves Rigel Pharmaceuticals' drug for rare bleeding disorder

The U.S. Food and Drug Administration on Tuesday approved Rigel Pharmaceuticals Inc's treatment for a rare bleeding disorder.

BRIEF-Rigel Makes Statement Regarding Website Error

* FDA IS CONTINUING ITS REVIEW OF NDA AND PDUFA ACTION DATE FOR FOSTAMATINIB NDA IS APRIL 17

REFILE-BRIEF-Rigel Announces Topline Data From Phase 2 Study Of Fostamatinib

* RIGEL ANNOUNCES TOPLINE DATA FROM PROOF-OF-CONCEPT PHASE 2 STUDY OF FOSTAMATINIB IN IGA NEPHROPATHY

BRIEF-Rigel Pharma Files For Mixed Shelf Of Up To $200 Mln

* RIGEL PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING Source text (http://bit.ly/2FoyDNx) Further company coverage:

BRIEF-Rigel Pharma Q4 Loss Per Share $0.18

* RIGEL ANNOUNCES FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

BRIEF-Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib

* RIGEL PHARMACEUTICALS - FDA HAS CONFIRMED IT DOES NOT PLAN TO CONVENE ONCOLOGY DRUGS ADVISORY COMMITTEE MEETING TO DISCUSS NDA FOR FOSTAMATINIB

BRIEF-Rigel Announces Resignation Of Ryan Maynard, Executive Vice President And CFO Effective December 31, 2017

* RESIGNATION OF RYAN MAYNARD, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE DECEMBER 31, 2017

BRIEF-Rigel announces Q3 loss of $0.14 per share

* Rigel announces third quarter 2017 financial results and provides company update

BRIEF-Rigel announces pricing of public offering of common stock

* Says public offering of 18.1 million common shares priced at $3.35 per share Source text for Eikon: Further company coverage:

BRIEF-Rigel announces proposed public offering of common stock

* Rigel Pharmaceuticals Inc - intends to offer and sell up to $40 million of shares of its common stock in an underwritten public offering

BRIEF-RIGEL PHARMACEUTICALS SAYS FOSTAMATINIB MEETS PRE-SPECIFIED GOAL IN STAGE 1 OF AIHA PHASE 2 STUDY

* FOSTAMATINIB MEETS PRE-SPECIFIED PRIMARY ENDPOINT IN STAGE 1 OF AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) PHASE 2 STUDY

BRIEF-Rigel provides update on FDA review of fostamatinib for ITP

* Rigel provides update on FDA review of fostamatinib for ITP

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up